On the one hand, activation of p53 induces immune-related gene expression in cancer cells such as TRAIL, TLRs, and FAS, regulates the STING pathway, influences the programmed death-ligand 1 (PD-L1) and supports cytotoxic T cell-induced tumor cell death resulting in modulation of anti-tumor immunity [35–37]. This evidence concerns the gene TP53 and cancer.